Search results
Showing 1441 to 1455 of 7680 results
Vedolizumab for treating moderately to severely active ulcerative colitis (TA342)
Evidence-based recommendations on vedolizumab (Entyvio) for treating moderate to severe ulcerative colitis in adults.
Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343)
Evidence-based recommendations on obinutuzumab (Gazyvaro) with chlorambucil for untreated chronic lymphocytic leukaemia in adults.
NICE is unable to make a recommendation about the use in the NHS of paclitaxel as albumin-bound nanoparticles with carboplatin for adults with untreated non-small-cell lung cancer when potentially curative surgery or radiation therapy or both are unsuitable, because no evidence submission was received from Celgene technology.
Show all sections
Sections for TA362
Everolimus for preventing organ rejection in liver transplantation (TA348)
Evidence-based recommendations on everolimus (Certican) for preventing organ rejection in adults having a liver transplant.
Secukinumab for treating moderate to severe plaque psoriasis (TA350)
Evidence-based recommendations on secukinumab (Cosentyx) for treating plaque psoriasis in adults.
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events, such as heart attack and stroke, after acute coronary syndrome in adults.
Empagliflozin in combination therapy for treating type 2 diabetes (TA336)
Evidence-based recommendations on empagliflozin (Jardiance) in combination therapy for treating type 2 diabetes.
Omalizumab for previously treated chronic spontaneous urticaria (TA339)
Evidence-based recommendations on omalizumab (Xolair) for treating severe chronic spontaneous urticaria in people of 12 and over.
Evidence-based recommendations on axitinib (Inlyta) for previously treated advanced renal cell carcinoma in adults.
NICE is unable to make a recommendation about the use in the NHS of regorafenib for metastatic colorectal cancer after treatment for metastatic disease because no evidence submission was received from Bayer for the technology.
Show all sections
Sections for TA334
Rifaximin for preventing episodes of overt hepatic encephalopathy (TA337)
Evidence-based recommendations on rifaximin (Targaxan) for preventing episodes of hepatic encephalopathy in adults.
Nalmefene for reducing alcohol consumption in people with alcohol dependence (TA325)
Evidence-based recommendations on nalmefene (Selincro) for reducing alcohol consumption in adults with alcohol dependence.
Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (TA326)
Evidence-based recommendations on imatinib (Glivec) for treating gastrointestinal stromal tumours in adults.
Evidence-based recommendations on dabigatran etexilate (Pradaxa) for treating and preventing deep vein thrombosis and pulmonary embolism in adults.
Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.